Related Experiment Videos
Serum thyroglobulin differentiated thyroid carcinoma: histological and metastatic classification
Acta Endocrinologica
|October 1, 1981
Summary
Serum thyroglobulin (Tg) levels aid in differentiated thyroid cancer management. Elevated Tg indicates metastases, particularly bone metastases, and helps exclude thyroid cancer in unknown primary bone metastases.
Area of Science:
- Endocrinology
- Oncology
- Nuclear Medicine
Background:
- Differentiated thyroid carcinoma (DTC) management involves monitoring tumor markers.
- Serum thyroglobulin (Tg) is a key biomarker for thyroid cancer recurrence and metastasis.
Purpose of the Study:
- To evaluate the utility of serum thyroglobulin (Tg) levels in patients with differentiated thyroid carcinoma.
- To correlate Tg levels with treatment status, histology, and metastatic sites.
Main Methods:
- Serum Tg levels were measured in 112 patients with differentiated thyroid carcinoma.
- Patients were categorized by pre-operative, post-operative, and post-radioiodine treatment status.
- Tg levels were analyzed in relation to residual disease, remission, histology, and sites of metastasis.
Main Results:
- Normal Tg levels were observed in patients in remission with no residual neck mass.
- Metastatic patients exhibited a wide range of Tg levels.
- Follicular thyroid carcinoma showed higher serum Tg than papillary type.
- Bone metastases were associated with significantly higher Tg levels compared to lung or lymph node metastases.
Conclusions:
- Serum Tg is a valuable tool for monitoring differentiated thyroid carcinoma.
- Tg levels can indicate the presence and extent of metastases.
- Serum Tg estimation is useful for excluding a thyroid primary in cases of bone metastases with unknown origin.